AzTrials
AzTrials

Binge-Eating DisorderCHRONO-BENCT04724668

The Role of the Circadian System in Binge Eating Disorder

A study testing Melatonin (3hrs before DLMO), Morning light version 1 and Morning light version 2 in people with Binge-Eating Disorder and Circadian Rhythm Disorders, run by University of Cincinnati at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Binge eating disorder (BED) shows prominent circadian features that suggest a delay in circadian phase, and preliminary evidence shows binge eating may be responsive to chronobiological interventions, implicating a circadian system dysfunction in its pathophysiology. Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
What is being tested?
Melatonin (3hrs before DLMO), Morning light version 1 and Morning light version 2
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
84 participants
Where
1 siteUnited States
Study dates
15 Jan 2021to 30 May 2025
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Binge Eating Disorder (BED) group inclusion criteria:

  1. Age 18-50 years, inclusive
  2. Female or male
  3. BMI ≥30 kg/m2
  4. Current BED diagnoses by Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria confirmed by Structured Clinical Interview (SCID-5)
  5. Moderate or severe BED (≥3 binge eating episodes/week in the past 14 days)
  6. No current pharmacological treatment for BED, or if receiving treatment dose stable for ≥ 2 months
  7. If receiving psychotherapy, intervention must be stable for ≥ 3 months and agree to continue during the study
  8. Other psychiatric disorders will be permitted as long as they are not more than moderate in severity
  9. Using an effective contraceptive method (participants of childbearing potential)

BED exclusion criteria:

  1. Current severe comorbid psychopathology (i.e; mania, severe major depressive disorder (MDD), psychosis)
  2. Current (past month) substance use disorder (caffeine and nicotine allowed)
  3. Chronic use of bright light therapy (BLT) or melatonin in the past month
  4. Current contraindication or history of melatonin allergy or non-tolerability;
  5. Current contraindication or history of BLT non-tolerability
  6. Significant risk of suicide according to Columbia-Suicide Severity Rating Scale (CSSRS) or clinical judgment, or suicidal behavior in the past year
  7. Routine shift work (night work) in the past month
  8. Travel across more than 1 time zone in the past two weeks
  9. Current treatment with medication known to affect the circadian system or melatonin measurements, including: B-blockers, hypnotic sedatives, anticoagulants, antidiabetes drugs, oral corticosteroids, and other immunosuppressant medication
  10. Current lesions or bleeding in the oral cavity, as it may alter DLMO measurements
  11. Clinically significant unstable medical conditions as judged by the clinician, including: seizure or neurodegenerative disorders, thyroid conditions, autoimmune disorders, and cardiovascular disease
  12. Pregnancy or breastfeeding
  13. Participation in a clinical trial in the past month
  14. Suspected intelligence quotient (IQ) <80
  15. Any other clinically relevant reason as judged by the clinician

Control group inclusion criteria:

  1. Age 18-50 years, inclusive
  2. Female or male;
  3. BMI ≥30 kg/m2
  4. No current or lifetime history of BED or bulimia nervosa diagnoses confirmed by SCID-5
  5. No current (past month) psychiatric diagnosis according to SCID-5, including substance use disorders (caffeine and nicotine allowed)
  6. No current psychiatric or psychological treatment, or if receiving treatment dose/intervention stable for ≥ 2 months

Control group exclusion criteria:

  1. Clinically significant unstable medical conditions as judged by the clinician, including: seizure or neurodegenerative disorders, thyroid conditions, autoimmune disorders, and cardiovascular disease
  2. Chronic treatment with BLT or melatonin in the past month
  3. Routine shift work (work at night) in the past month
  4. Travel across more than 1 time zone in the past two weeks
  5. Significant risk of suicide according to CSSRS or clinical judgment, or suicidal behavior in the past year
  6. Current treatment with medication known to affect the circadian system or melatonin measurements, including, B-blockers, hypnotic sedatives, anticoagulants, antidiabetes drugs, oral corticosteroids, and other immunosuppressant medication
  7. Current lesions or bleeding in the oral cavity, as it may alter DLMO measurements
  8. Pregnant or breastfeeding
  9. Participation in a clinical trial in the past month
  10. Suspected IQ<80
  11. Any other clinically relevant reason as judged by the clinician

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Lindner Center of HOPE / University of Cincinnati

    Mason, Ohio, 45040

Other trials in United States

About this study

Binge eating disorder (BED) shows prominent circadian features that suggest a delay in circadian phase, and preliminary evidence shows binge eating may be responsive to chronobiological interventions, implicating a circadian system dysfunction in its pathophysiology. What remains lacking, however, is comprehensive knowledge of the characteristics of circadian system dysfunction in BED, and whether this dysfunction represents a therapeutic target in BED. There is therefore a critical need to characterize circadian system dysfunction in BED, and evaluate it as a potential therapeutic target. Without such information, the understanding on the role of the circadian system in BED and its potential as a new therapeutic target will remain limited.

Read the detailed description

The overall objective of the research strategy will be to characterize circadian system dysfunction in BED and its potential as a therapeutic target. The central hypothesis is that a circadian system dysfunction (phase delay) plays a role in the pathophysiology of BED, and that advancing the circadian phase will improve BED symptoms. To attain the overall objectives, the following specific aims will be pursued in two phases:

Specific aim 1) To characterize circadian system dysfunction in BED (Phase 1). Circadian system function will be evaluated in 80 adult (18 to 50yrs) obese subjects, 40 with BED and 40 without BED as a control group matched by age, body mass index (BMI), and gender, during a two-week observational phase. Based on preliminary data, the working hypothesis is that DLMO (the primary outcome measure) and secondary circadian parameters (i.e., locomotor activity acrophase) will occur later in the BED group compared with the control group, and a later circadian phase will be associated with worse BED clinical features.

Specific aim 2) To evaluate circadian phase as a predictive biomarker for response to a chronobiological intervention and evidence of circadian system target engagement in BED (Phase 2). A mechanistic clinical trial with a 4-week double-blinded, randomized, sham/placebo controlled study design will evaluate the effect of a combination of morning lights+Melatonin/placebo on the circadian system and eating behavior on 40 BED subjects that complete phase 1. Subjects will be randomized to receive a combination of morning lights at usual wake time + Melatonin(3mg) or placebo (3hr before DLMO). Based on preliminary data, the working hypothesis is that a chronobiological intervention will induce a greater DLMO advance (primary outcome measure), greater decrease in binge eating days/week (secondary outcome measure), and change in exploratory metabolic outcomes. In addition, a later baseline DLMO (secondary outcome) will predict change in binge eating days/week and metabolic parameters in response to a chronobiological intervention.

Being tested
Melatonin (3hrs before DLMO), Placebo (3hrs before DLMO), Morning light version 1, Morning light version 2
Keywords
Binge eating, Circadian
Medical subject headings
Binge-Eating Disorder, Chronobiology Disorders, Bulimia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Melatonin (3hrs before DLMO)Dietary supplement

    Melatonin 3mg (3hrs before DLMO)

  • Placebo (3hrs before DLMO)Dietary supplement

    Placebo capsule (3hrs before DLMO)

  • Morning light version 1Device

    Morning light version

  • Morning light version 2Device

    Morning light version

Study groups in NCT04724668
Study groupRoleWhat they receive
Morning light version+ MelatoninOtherMorning light version and melatonin 3mg capsule (3hrs before DLMO)
Receives: Dietary Supplement: Melatonin (3hrs before DLMO); Device: Morning light version 1
Morning light version+ PlaceboOtherMorning light version and placebo capsule (3hrs before DLMO)
Receives: Dietary Supplement: Placebo (3hrs before DLMO); Device: Morning light version 2
Control groupNo interventionAdults with obesity without BED, only phase1 and did not receive intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Phase 1 Dim Light Melatonin Onset (DLMO)

    Difference in mean DLMO (measured in hours) between subjects with binge eating disorder (BED) and control subjects without BED.

    Measured: Phase 1 baseline (visit 0)

  2. Phase 2 Dim Light Melatonin Onset (DLMO)

    Differences in DLMO (measured in hours) change from baseline to endpoint between two intervention groups will be analyzed using an ANCOVA model with age as a covariate. Controls did not participate in the intervention (phase 2).

    Measured: Phase 2 baseline (visit 0) to endpoint, on average one month.

Secondary outcomes (2)
  1. Phase 1 MEQ

    Difference in mean Morningness Eveningness Questionnaire scores (MEQ) between BED and control subjects without BED. MEQ score range 18 to 86, lower scores indicate more eveningness, higher scores indicate more morningness.

    Measured: Phase 1 baseline (visit 0)

  2. Phase 2 Binge Eating Days/Week

    Differences in Binge eating days/week from baseline to endpoint between groups will be analyzed using an ANCOVA model with age as a covariate.

    Measured: Phase 2 baseline (visit 0) to endpoint, on average one month.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Jan 2021
  2. Study start15 Jan 2021
  3. Primary completion30 May 2025
  4. Study completion30 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
The specific aims will be completed in a two-phase experimental approach. In the first phase (specific aim 1), subjects with obesity with BED (n=40) and without BED (n=40) will participate in a 2-week longitudinal study. In the second phase (specific aim 2), only BED subjects that complete phase 1 will rollover for a 4-week intervention study.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
84 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04724668
Sponsor's protocol ID
2020-0345
Other IDs
1K23MH120503-01A1
Acronym
CHRONO-BE
Status last verified
Jul 2026
First submitted
20 Jan 2021
Last updated
21 Aug 2026
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No: However, individual participant data may be shared with other researchers upon request.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in